Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!
5.6.2020 12:10:00 EEST | Business Wire | Press release
Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value.
As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service.
“Datalytyx said they could get their DataOps Platform in and working within three weeks, and they did. What’s more, the capability it’s bringing us, to set up, monitor and amend data feeds simply and rapidly, is really quite transformational.”
David Galloway, Strategy and Business Insight Manager for BOC
And at wejo, the connected car company, they have been innovating in connected car data to create ground-breaking products and services that revolutionise the way people travel. By generating insights to harness the value of that data, they enable smarter, safer and more sustainable journeys for all. Datalytyx have deployed their DataOps for Snowflake platform to orchestrate multiple Snowflake cloud data platform tenants accessing a single primary Snowflake datastore using Snowflake Secure Data Sharing, plus Jupyter Notebooks and Tableau Online at the front end of each tenant.
"Snowflake and Datalytyx DataOps are at the heart of these new ideas for secure data sharing with our customers, and some of the new geospatial features from Snowflake will enhance this further. An initial proof of concept demonstrated how the Datalytyx thinking would complement our own, to deliver ADEPT Preview faster and more confidently than we could by ourselves. Their DataOps based approach could deliver repeatable, consistent, disposable and secure data environments for our customers in ¼ of the time."
Steve Pimblett, CIO and CDO of wejo
Snowflake Chief Technical Evangelist, Kent Graziano said “Organizations today require business agility without any sacrifices to data governance and security. Datalytyx Data Ops for Snowflake can enable customers to leverage the elastic scaling and single, integrated, secured platform benefits of Snowflake, enhanced by the CI/CD automation, audit, and governance features of this new product from Datalytyx to help achieve that business agility.”
“Snowflake delivers unique value to our customers.” said Justin Mullen, CEO of Datalytyx. “We have been working on the philosophy of DataOps and #TrueDataOps with industry pioneers for the last 12 months. #TrueDataOps has only become possible because of a number of significant and critical advancements that today are unique to Snowflake’s Cloud Data Platform. “Our DataOps for Snowflake platform enables organisations to focus on value-led development of pipelines (e.g. reduce fraud, improve customer experience, increase uptake, identify opportunities, etc.) to produce analytical processes that support and enable the achievement of that value.”
About Datalytyx
Datalytyx enables organisations to deliver better data, faster, to their customers. In 2018 Datalytyx started looking at how we could reduce the time to insight, and accelerate the time to value for our customers. In 2019 we have been developing our technologies around the emerging discipline of DataOps (with a clear focus on the true principles of DevOps) and extracting value from volume in IoT data. And in 2020 we publicly shared our DataOps Philosophy (#TrueDataOps) and released our DataOps for Snowflake platform supported by our patent-pending IoT Data Compression algorithm, Datalytyx Gallium.
Datalytyx makes it easier for you to do cool, critical, valuable and smart things with data. We provide the technology, skills, and resources to deliver better data faster. Reduced risk, fewer headaches and lower overall cost.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200605005054/en/
Contact information
Justin Mullen
+44 7710 482520
justin.mullen@datalytyx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom